A population pharmacokinetic model based on HPTN 077 of long‐acting injectable cabotegravir for HIV PrEP
Yifan Yu(University at Buffalo, State University of New York), Raphael J. Landovitz(APLA Health), Marybeth McCauley(Family Health International 360), Craig W. Hendrix(Unknown), Ethel D. Weld(Johns Hopkins University), Robert R. Bies(University at Buffalo, State University of New York), Mark A. Marzinke(Family Health International 360), Susan L. Ford(Research Triangle Park Foundation), Kristin L. Bigos(Johns Hopkins University)
Cited by 11
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|891
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
|New England Journal of Medicine|2016|768